lercanidipine
Small moleculeexperimental
Lercanidipine (INN) is an antihypertensive drug. It belongs to the dihydropyridine class of calcium channel blockers, which work by relaxing and opening the blood vessels allowing the blood to circulate more freely around the body. This lowers the blood pressure and allows the heart to work more efficiently. — Wikipedia
Clinical trial activity
11 trials · 13 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
1
Phase 4
6
Earliest trial started May 1, 2004 (NCT00160498)
Timeline
Indications
Approved for
Mechanism of action
Voltage-gated L-type calcium channel blocker
- Voltage-gated L-type calcium channelINHIBITOR
Voltage-gated L-type calcium channel inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(c2ccccc2)c2ccccc2)C1c1cccc([N+](=O)[O-])c1- Mol. weight
- 611.74 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL250270 ↗
- WikipediaLercanidipine ↗
- ChEMBLCHEMBL2106419 ↗
Also known as
- biohorm brand of lercanidipine hydrochloride
- cardiovasc
- cardiovasc
- carmen
- carmen
- corifeo
- corifeo
- lercadip
- lercadip
- lercadip
- lercan
- lercan
- lercanidipine
- lercanidipine
- lercanidipine
- lercanidipine
- lercanidipine
- lercanidipine
- lercanidipine
- lercanidipine
- lercanidipine hcl
- lercanidipine hcl
- lercanidipine hcl
- lercanidipine hydrochloride
- lercanidipine hydrochloride
- lercanidipine hydrochloride
- lercanidipine hydrochloride
- lercanidipine hydrochloride
- lercanidipine hydrochloride
- lercanil
- lercanil
- lercapin
- lercapin
- lercaton
- lercaton
- lerdip
- lerkamen
- lerkamen
- lerzam
- lerzam
- masnidipine
- methyl-1,1-dimethyl-2-(n-(3,3-diphenylpropyl)-n-methylamino)ethyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
- rec 15-2375
- rec-15-2375
- rec-15/2375
- rec-15/2375
- renovia
- renovia
- vasodip
- vasodip
- zandip
- zandip
- zanicor
- zanicor
- zanidip
- zanidip
- zanidip
- zanidip
- zanidip
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01928628 | Phase 3 | May 1, 2012 | LG |
| NCT01520285 | Phase 4 | Dec 1, 2011 | Lee's Pharmaceutical |
| NCT02594410 | Phase 4 | Sep 1, 2011 | Lee's Pharmaceutical |
| NCT01211314 | Phase 4 | Jan 1, 2011 | Dexcel Pharma Technologies Ltd., Technion University, Tel Aviv University |
| NCT01180413 | Phase 4 | Dec 1, 2010 | Aarhus University |
| NCT01093807 | Phase 2 | Mar 1, 2010 | Recordati |
| NCT01122251 | Phase 2 | Dec 1, 2009 | LG |
| NCT00741585 | Phase 4 | Sep 1, 2008 | University of Vigo |
| NCT00564057 | Phase 4 | Sep 1, 2007 | University of Insubria |
| NCT00424801 | N/A | Jan 1, 2007 | Aarhus University, Danish Cardiovascular Research Academy, Danish Heart Foundation, Novartis |
| NCT00160498 | N/A | May 1, 2004 | Hoosier Cancer Research Network |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (13)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aarhus University | Academic/Hospital | 2 | 2 | 2 | 2007 |
| Lee's Pharmaceutical | For profit | 2 | 2 | 1 | 2011 |
| LG | For profit | 2 | 2 | 2 | 2009 |
| Danish Cardiovascular Research Academy | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Danish Heart Foundation | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Dexcel Pharma Technologies Ltd. | For profit | 1 | 0 | 1 | 2011 |
| Hoosier Cancer Research Network | Academic/Hospital | 1 | 1 | 1 | 2004 |
| Novartis | For profit | 1 | 0 | 1 | 2007 |
| Recordati | For profit | 1 | 1 | 1 | 2010 |
| Technion University | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Tel Aviv University | Academic/Hospital | 1 | 1 | 1 | 2011 |
| University of Insubria | Academic/Hospital | 1 | 1 | 1 | 2007 |
| University of Vigo | Academic/Hospital | 1 | 1 | 1 | 2008 |
13 organizations
Page 1 / 1